These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8353168)

  • 1. 3H-spiroperidol binding to peripheral mononuclear cells in schizophrenic and healthy subjects.
    Wodarz N; Fritze J; Riederer P; Beckmann H
    Biol Psychiatry; 1993 May; 33(10):727-33. PubMed ID: 8353168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3H-spiperone binding to peripheral mononuclear cells in psychiatric in-patients.
    Wodarz N; Fritze J; Riederer P
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Apr; 20(3):459-70. PubMed ID: 8771601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in [3H]-spiperone binding to peripheral blood lymphocytes from neuroleptic responsive and nonresponsive schizophrenic patients.
    Grodzicki J; Pardo M; Schved G; Schlosberg A; Fuchs S; Kanety H
    Biol Psychiatry; 1990 Jun; 27(12):1327-30. PubMed ID: 1973057
    [No Abstract]   [Full Text] [Related]  

  • 4. The sequestration of [3H]spiperone by lymphocytes in schizophrenics and their first-degree relatives: a limited vulnerability marker?
    Griffiths RS; Chung-a-on KO; Griffiths KD; Payne JW; Davies JI
    J Psychiatr Res; 1992 Jan; 26(1):77-84. PubMed ID: 1560411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of 3H-spiperone by lymphocytes in schizophrenia.
    Itzchaky S; Lerer B; Ebstein RP
    J Psychiatr Res; 1989; 23(3-4):221-7. PubMed ID: 2635219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3H-spiperone binding in platelet membranes: a possible biological marker for schizophrenia.
    Sethi BB; Kumar P; Agarwal AK; Seth PK; Trivedi JK
    Acta Psychiatr Scand; 1986 Feb; 73(2):186-90. PubMed ID: 3705995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3H-spiroperidol binding to human peripheral mononuclear cells: methodological aspects.
    Wodarz N; Fritze J; Kornhuber J; Riederer P
    Biol Psychiatry; 1992 Feb; 31(3):291-303. PubMed ID: 1532133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet serotonin-2 receptors in schizophrenia: effects of illness and neuroleptic treatment.
    Pandey SC; Sharma RP; Janicak PG; Marks RC; Davis JM; Pandey GN
    Psychiatry Res; 1993 Jul; 48(1):57-68. PubMed ID: 8105499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.
    Kornhuber J; Riederer P; Reynolds GP; Beckmann H; Jellinger K; Gabriel E
    J Neural Transm; 1989; 75(1):1-10. PubMed ID: 2563750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.
    Pearlson GD; Wong DF; Tune LE; Ross CA; Chase GA; Links JM; Dannals RF; Wilson AA; Ravert HT; Wagner HN
    Arch Gen Psychiatry; 1995 Jun; 52(6):471-7. PubMed ID: 7771917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte 3H-spiroperidol binding in schizophrenia: preliminary findings.
    Rotstein E; Mishra RK; Singal DP; Barone D
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):729-32. PubMed ID: 6686701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3H-spiperone binding to lymphocytes in neuroleptic-naive-schizophrenia and the effect of neuroleptic treatment.
    Laufer N; Spivak B; Holdengreber V; Zipser J; Kosower N; Ragolsky M; Weizman A
    Clin Neuropharmacol; 1999; 22(2):110-4. PubMed ID: 10202608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of dopamine agonist and antagonist binding sites in mammalian retina.
    Makman MH; Dvorkin B; Horowitz SG; Thal LJ
    Brain Res; 1980 Aug; 194(2):403-18. PubMed ID: 6770965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
    Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
    Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocytes of healthy subjects and schizophrenic patients possess no high-affinity binding sites for spiroperidol.
    Rao ML; Deister A; Roth A
    Pharmacopsychiatry; 1990 Jul; 23(4):176-81. PubMed ID: 2381986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
    Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
    Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of brain neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Am J Psychiatry; 1980 Feb; 137(2):191-7. PubMed ID: 6101525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodology of 3H-spiperone binding to lymphocytes.
    Bondy B; Ackenheil M; Engel RR
    J Psychiatr Res; 1990; 24(1):83-92. PubMed ID: 1694898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
    Rupniak NM; Kilpatrick G; Hall MD; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1984; 84(4):512-9. PubMed ID: 6441952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.